CSL Vifor And Travere's FILSPARI Receives Temporary Approval From Swissmedic For IgA Nephropathy Patients

Benzinga · 10/17 07:04

Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial